Intrinsic value of Cerecor - CERC

Previous Close

$3.77

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$3.77

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of CERC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  45
  69
  103
  149
  210
  289
  388
  510
  656
  829
  1,029
  1,258
  1,517
  1,805
  2,122
  2,468
  2,843
  3,246
  3,677
  4,134
  4,617
  5,126
  5,660
  6,218
  6,802
  7,411
  8,045
  8,704
  9,390
  10,103
Variable operating expenses, $m
  662
  1,022
  1,526
  2,213
  3,121
  4,290
  5,757
  7,559
  9,725
  12,283
  15,249
  18,643
  22,471
  26,736
  31,437
  36,568
  42,124
  48,094
  54,468
  61,239
  68,396
  75,931
  83,841
  92,120
  100,767
  109,784
  119,174
  128,945
  139,103
  149,662
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  662
  1,022
  1,526
  2,213
  3,121
  4,290
  5,757
  7,559
  9,725
  12,283
  15,249
  18,643
  22,471
  26,736
  31,437
  36,568
  42,124
  48,094
  54,468
  61,239
  68,396
  75,931
  83,841
  92,120
  100,767
  109,784
  119,174
  128,945
  139,103
  149,662
Operating income, $m
  -618
  -953
  -1,424
  -2,064
  -2,911
  -4,001
  -5,369
  -7,049
  -9,069
  -11,454
  -14,219
  -17,384
  -20,954
  -24,931
  -29,315
  -34,100
  -39,280
  -44,847
  -50,792
  -57,105
  -63,779
  -70,806
  -78,181
  -85,901
  -93,965
  -102,373
  -111,130
  -120,240
  -129,714
  -139,560
EBITDA, $m
  -614
  -949
  -1,419
  -2,059
  -2,906
  -3,995
  -5,362
  -7,041
  -9,059
  -11,443
  -14,209
  -17,372
  -20,939
  -24,914
  -29,294
  -34,076
  -39,253
  -44,816
  -50,757
  -57,065
  -63,734
  -70,757
  -78,127
  -85,842
  -93,900
  -102,302
  -111,053
  -120,157
  -129,624
  -139,463
Interest expense (income), $m
  0
  0
  0
  1
  2
  3
  5
  8
  10
  14
  18
  23
  29
  35
  43
  51
  60
  70
  81
  93
  105
  118
  132
  147
  162
  178
  195
  213
  231
  250
  270
Earnings before tax, $m
  -618
  -953
  -1,425
  -2,066
  -2,914
  -4,006
  -5,376
  -7,059
  -9,083
  -11,472
  -14,242
  -17,413
  -20,989
  -24,974
  -29,366
  -34,160
  -39,350
  -44,928
  -50,884
  -57,210
  -63,897
  -70,938
  -78,328
  -86,063
  -94,143
  -102,568
  -111,343
  -120,472
  -129,964
  -139,829
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -618
  -953
  -1,425
  -2,066
  -2,914
  -4,006
  -5,376
  -7,059
  -9,083
  -11,472
  -14,242
  -17,413
  -20,989
  -24,974
  -29,366
  -34,160
  -39,350
  -44,928
  -50,884
  -57,210
  -63,897
  -70,938
  -78,328
  -86,063
  -94,143
  -102,568
  -111,343
  -120,472
  -129,964
  -139,829

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  68
  105
  157
  228
  322
  442
  594
  780
  1,003
  1,267
  1,574
  1,924
  2,319
  2,760
  3,245
  3,774
  4,348
  4,964
  5,622
  6,321
  7,060
  7,837
  8,654
  9,508
  10,401
  11,331
  12,301
  13,309
  14,358
  15,448
Adjusted assets (=assets-cash), $m
  68
  105
  157
  228
  322
  442
  594
  780
  1,003
  1,267
  1,574
  1,924
  2,319
  2,760
  3,245
  3,774
  4,348
  4,964
  5,622
  6,321
  7,060
  7,837
  8,654
  9,508
  10,401
  11,331
  12,301
  13,309
  14,358
  15,448
Revenue / Adjusted assets
  0.662
  0.657
  0.656
  0.654
  0.652
  0.654
  0.653
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
  0.654
Average production assets, $m
  13
  20
  30
  43
  60
  83
  111
  146
  188
  238
  295
  361
  435
  518
  609
  708
  816
  932
  1,055
  1,186
  1,325
  1,471
  1,624
  1,785
  1,952
  2,127
  2,309
  2,498
  2,695
  2,899
Working capital, $m
  -5
  -7
  -11
  -15
  -22
  -30
  -40
  -53
  -68
  -85
  -106
  -130
  -156
  -186
  -219
  -254
  -293
  -334
  -379
  -426
  -476
  -528
  -583
  -640
  -701
  -763
  -829
  -897
  -967
  -1,041
Total debt, $m
  9
  22
  40
  65
  97
  139
  192
  257
  335
  427
  534
  657
  795
  948
  1,117
  1,302
  1,502
  1,717
  1,947
  2,191
  2,449
  2,720
  3,005
  3,303
  3,615
  3,940
  4,278
  4,630
  4,996
  5,376
Total liabilities, $m
  24
  37
  55
  80
  112
  154
  207
  272
  350
  442
  549
  672
  809
  963
  1,132
  1,317
  1,517
  1,732
  1,962
  2,206
  2,464
  2,735
  3,020
  3,318
  3,630
  3,955
  4,293
  4,645
  5,011
  5,391
Total equity, $m
  44
  68
  102
  149
  210
  288
  387
  508
  653
  825
  1,025
  1,253
  1,510
  1,796
  2,112
  2,457
  2,830
  3,232
  3,660
  4,115
  4,596
  5,102
  5,634
  6,190
  6,771
  7,377
  8,008
  8,664
  9,347
  10,056
Total liabilities and equity, $m
  68
  105
  157
  229
  322
  442
  594
  780
  1,003
  1,267
  1,574
  1,925
  2,319
  2,759
  3,244
  3,774
  4,347
  4,964
  5,622
  6,321
  7,060
  7,837
  8,654
  9,508
  10,401
  11,332
  12,301
  13,309
  14,358
  15,447
Debt-to-equity ratio
  0.200
  0.320
  0.390
  0.440
  0.460
  0.480
  0.500
  0.510
  0.510
  0.520
  0.520
  0.520
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
Adjusted equity ratio
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651
  0.651

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -618
  -953
  -1,425
  -2,066
  -2,914
  -4,006
  -5,376
  -7,059
  -9,083
  -11,472
  -14,242
  -17,413
  -20,989
  -24,974
  -29,366
  -34,160
  -39,350
  -44,928
  -50,884
  -57,210
  -63,897
  -70,938
  -78,328
  -86,063
  -94,143
  -102,568
  -111,343
  -120,472
  -129,964
  -139,829
Depreciation, amort., depletion, $m
  4
  4
  4
  5
  5
  6
  7
  8
  9
  11
  10
  12
  15
  17
  20
  24
  27
  31
  35
  40
  44
  49
  54
  59
  65
  71
  77
  83
  90
  97
Funds from operations, $m
  -614
  -950
  -1,421
  -2,062
  -2,909
  -4,000
  -5,369
  -7,051
  -9,073
  -11,461
  -14,232
  -17,401
  -20,975
  -24,957
  -29,345
  -34,137
  -39,323
  -44,897
  -50,849
  -57,171
  -63,853
  -70,889
  -78,274
  -86,004
  -94,078
  -102,498
  -111,266
  -120,388
  -129,874
  -139,733
Change in working capital, $m
  -2
  -2
  -4
  -5
  -6
  -8
  -10
  -13
  -15
  -18
  -21
  -24
  -27
  -30
  -33
  -36
  -39
  -42
  -44
  -47
  -50
  -52
  -55
  -58
  -60
  -63
  -65
  -68
  -71
  -73
Cash from operations, $m
  -613
  -947
  -1,417
  -2,057
  -2,903
  -3,992
  -5,359
  -7,038
  -9,058
  -11,443
  -14,212
  -17,378
  -20,948
  -24,927
  -29,313
  -34,101
  -39,285
  -44,856
  -50,805
  -57,123
  -63,803
  -70,837
  -78,219
  -85,946
  -94,018
  -102,435
  -111,200
  -120,320
  -129,803
  -139,659
Maintenance CAPEX, $m
  0
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -12
  -15
  -17
  -20
  -24
  -27
  -31
  -35
  -40
  -44
  -49
  -54
  -59
  -65
  -71
  -77
  -83
  -90
New CAPEX, $m
  -5
  -7
  -10
  -13
  -18
  -23
  -28
  -35
  -42
  -50
  -58
  -66
  -74
  -83
  -91
  -99
  -108
  -116
  -124
  -131
  -139
  -146
  -153
  -160
  -168
  -175
  -182
  -189
  -197
  -205
Cash from investing activities, $m
  -5
  -7
  -11
  -14
  -19
  -25
  -31
  -39
  -47
  -56
  -66
  -76
  -86
  -98
  -108
  -119
  -132
  -143
  -155
  -166
  -179
  -190
  -202
  -214
  -227
  -240
  -253
  -266
  -280
  -295
Free cash flow, $m
  -618
  -954
  -1,428
  -2,071
  -2,922
  -4,016
  -5,390
  -7,077
  -9,105
  -11,499
  -14,277
  -17,453
  -21,034
  -25,024
  -29,421
  -34,221
  -39,416
  -44,999
  -50,959
  -57,290
  -63,981
  -71,027
  -78,421
  -86,161
  -94,245
  -102,675
  -111,453
  -120,587
  -130,083
  -139,954
Issuance/(repayment) of debt, $m
  9
  13
  18
  25
  33
  42
  53
  65
  78
  92
  107
  122
  138
  154
  169
  185
  200
  215
  230
  244
  258
  271
  285
  298
  311
  325
  338
  352
  366
  380
Issuance/(repurchase) of shares, $m
  634
  978
  1,459
  2,112
  2,975
  4,084
  5,475
  7,180
  9,228
  11,644
  14,442
  17,641
  21,247
  25,261
  29,682
  34,505
  39,724
  45,329
  51,313
  57,665
  64,378
  71,444
  78,859
  86,620
  94,724
  103,174
  111,974
  121,128
  130,646
  140,539
Cash from financing (excl. dividends), $m  
  643
  991
  1,477
  2,137
  3,008
  4,126
  5,528
  7,245
  9,306
  11,736
  14,549
  17,763
  21,385
  25,415
  29,851
  34,690
  39,924
  45,544
  51,543
  57,909
  64,636
  71,715
  79,144
  86,918
  95,035
  103,499
  112,312
  121,480
  131,012
  140,919
Total cash flow (excl. dividends), $m
  26
  36
  49
  66
  86
  110
  137
  168
  201
  237
  271
  310
  350
  390
  430
  469
  508
  546
  583
  619
  654
  689
  723
  757
  791
  825
  859
  893
  929
  966
Retained Cash Flow (-), $m
  -634
  -978
  -1,459
  -2,112
  -2,975
  -4,084
  -5,475
  -7,180
  -9,228
  -11,644
  -14,442
  -17,641
  -21,247
  -25,261
  -29,682
  -34,505
  -39,724
  -45,329
  -51,313
  -57,665
  -64,378
  -71,444
  -78,859
  -86,620
  -94,724
  -103,174
  -111,974
  -121,128
  -130,646
  -140,539
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -609
  -942
  -1,409
  -2,046
  -2,889
  -3,974
  -5,338
  -7,012
  -9,027
  -11,407
  -14,170
  -17,331
  -20,897
  -24,871
  -29,252
  -34,036
  -39,216
  -44,783
  -50,730
  -57,046
  -63,723
  -70,755
  -78,136
  -85,863
  -93,934
  -102,350
  -111,115
  -120,235
  -129,717
  -139,573
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -584
  -862
  -1,226
  -1,685
  -2,239
  -2,884
  -3,606
  -4,383
  -5,186
  -5,980
  -6,729
  -7,396
  -7,945
  -8,349
  -8,588
  -8,649
  -8,533
  -8,247
  -7,811
  -7,249
  -6,591
  -5,871
  -5,121
  -4,373
  -3,654
  -2,986
  -2,385
  -1,860
  -1,416
  -1,051
Current shareholders' claim on cash, %
  16.7
  2.9
  0.5
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

FINANCIAL RATIOS  of  Cerecor (CERC)

Valuation Ratios
P/E Ratio -2.2
Price to Sales 35.6
Price to Book 0
Price to Tangible Book
Price to Cash Flow -2.4
Price to Free Cash Flow -2.4
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -114.3%
Ret/ On Assets - 3 Yr. Avg. -118.5%
Return On Total Capital -152.4%
Ret/ On T. Cap. - 3 Yr. Avg. -171.6%
Return On Equity -246.2%
Return On Equity - 3 Yr. Avg. -393.2%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -1600%
EBITDA Margin - 3 Yr. Avg. -533.3%
Operating Margin -1600%
Oper. Margin - 3 Yr. Avg. -533.3%
Pre-Tax Margin -1600%
Pre-Tax Margin - 3 Yr. Avg. -533.3%
Net Profit Margin -1600%
Net Profit Margin - 3 Yr. Avg. -533.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CERC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CERC stock intrinsic value calculation we used $27.813137 million for the last fiscal year's total revenue generated by Cerecor. The default revenue input number comes from 0001 income statement of Cerecor. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CERC stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CERC is calculated based on our internal credit rating of Cerecor, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cerecor.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CERC stock the variable cost ratio is equal to 1492.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CERC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Cerecor.

Corporate tax rate of 27% is the nominal tax rate for Cerecor. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CERC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CERC are equal to 28.7%.

Life of production assets of 37.7 years is the average useful life of capital assets used in Cerecor operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CERC is equal to -10.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $27.859608 million for Cerecor - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33.845 million for Cerecor is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cerecor at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
LLY Eli Lilly 112.20 67.15  sell
ALKS Alkermes 34.09 69.78  str.buy
MRK Merck&Co 74.84 33.05  str.sell
BMY Bristol-Myers 53.27 71.64  hold
JNJ Johnson&Johnso 144.50 176.79  buy
TEVA Teva Pharmaceu 22.62 40.23  str.buy

COMPANY NEWS

▶ Cerecor Reports Third Quarter 2018 Results   [Nov-13-18 07:00AM  GlobeNewswire]
▶ CERC: Transformation Continues with Purchase of Ichorion Therapeutics, Inc   [Oct-02-18 09:20AM  Zacks Small Cap Research]
▶ Cerecor to Participate in Upcoming Healthcare Conferences   [Sep-26-18 01:00PM  GlobeNewswire]
▶ Baltimore's Cerecor buys New York biotech for $26.6M in stock   [11:29AM  American City Business Journals]
▶ Cerecor to Acquire Ichorion Therapeutics   [Sep-25-18 06:30AM  GlobeNewswire]
▶ CERC: Phase 1 Trial of CERC-301 in nOH Underway   [Aug-15-18 01:15PM  Zacks Small Cap Research]
▶ Cerecor Reports Second Quarter 2018 Financial Results   [Aug-09-18 06:30AM  GlobeNewswire]
▶ Penny Stocks to Watch for August 2018   [Jul-31-18 01:37PM  Investopedia]
▶ Cerecor Announces Expansion of Leadership Team   [Jul-16-18 06:00AM  GlobeNewswire]
▶ May Top Undervalued Stock   [May-19-18 10:02AM  Simply Wall St.]
▶ CERC: Converting into a Fully Independent Healthcare Company   [May-17-18 09:55AM  Zacks Small Cap Research]
▶ Cerecor Reports First Quarter 2018 Financial Results   [May-11-18 08:15AM  GlobeNewswire]
▶ Cerecor Appoints Simon Pedder to its Board of Directors   [Apr-09-18 08:00AM  Marketwired]
▶ Flavor Of The Month: inTEST And More   [Mar-28-18 10:02AM  Simply Wall St.]
▶ What Are The Drivers Of Cerecor Incs (NASDAQ:CERC) Risks?   [Dec-25-17 05:45PM  Simply Wall St.]
▶ Should You Buy Cerecor Inc (CERC) At This PE Ratio?   [Dec-08-17 10:33AM  Simply Wall St.]
▶ Is It The Right Time To Buy Cerecor Inc (CERC)?   [Nov-20-17 12:45PM  Simply Wall St.]
▶ Cerecor Announces Leadership Changes   [08:30AM  Marketwired]
▶ Cerecor Acquires TRx Pharmaceuticals   [08:15AM  Marketwired]
▶ Best Undervalued Stock Picks   [08:02AM  Simply Wall St.]
▶ Dilution Ahead For Cerecor Inc (CERC) Shareholders?   [Oct-05-17 05:46PM  Simply Wall St.]
▶ CERC: Encouraging Results from Proof-of-Concept Study of CERC-501 in MDD   [May-10-17 02:00PM  Zacks Small Cap Research]
▶ Cerecor Inc. Closes $5.0 Million Private Placement   [Apr-28-17 08:30AM  Marketwired]
▶ CERC: Ready to Move Ahead With Phase 2/3 Study of CERC-501 in MDD   [Mar-21-17 03:00PM  Zacks Small Cap Research]
▶ Cerecor Nicotine Withdrawal Drug Fails Study (CERC)   [Dec-06-16 04:09PM  Investopedia]
▶ Cerecor Depression Drug Fails Phase 2 Trial (CERC)   [Dec-01-16 12:45PM  Investopedia]
▶ What To Watch From The Upcoming Cerecor Inc (CERC) Release   [Oct-24-16 09:59AM  at Insider Monkey]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.